Nevian Lifescience PLC has entered into a new agreement with Sandoz Pharmaceuticals, a Slovenia-based export-import company, to expand its portfolio of pharmaceutical products in Bangladesh. The deal aims to enhance the distribution of Sandoz’s high-quality finished medicines, including complex generic drugs that require advanced manufacturing processes.

Nevian Lifescience, formerly known as Novartis Bangladesh Limited, will serve as the importer and distributor of selected Sandoz medicines within the Bangladeshi market. This partnership is expected to improve local access to a broader range of pharmaceuticals, particularly difficult-to-produce generics that are generally less available.

The company’s presence in Bangladesh spans nearly five decades. It originally started operations in 1973 as Ciba-Geigy (Bangladesh) Limited, established as a joint venture with Bangladesh Chemical Industries Corporation (BCIC), representing the government. After the global merger between Ciba and Sandoz, the entity was renamed Novartis Bangladesh Limited. In 2026, following the acquisition of a majority stake by Radiant Pharmaceuticals Limited, the firm was rebranded as Nevian Lifescience PLC.

This latest agreement with Sandoz represents a continuation of Nevian’s evolving international collaborations and reinforces its role in the Bangladeshi pharmaceutical landscape by expanding its product offerings and market reach.